Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
HIV prevalence and incidence among sexually active females in two districts of South Africa to determine microbicide trial feasibility
PLoS ONE, Volume 6, No. 8, Article e21528, Year 2011
Notification
URL copied to clipboard!
Description
Background: The suitability of populations of sexually active women in Madibeng (North-West Province) and Mbekweni (Western Cape), South Africa, for a Phase III vaginal microbicide trial was evaluated. Methods: Sexually active women 18-35 years not known to be HIV-positive or pregnant were tested cross-sectionally to determine HIV and pregnancy prevalence (798 in Madibeng and 800 in Mbekweni). Out of these, 299 non-pregnant, HIV-negative women were subsequently enrolled at each clinical research center in a 12-month cohort study with quarterly study visits. Results: HIV prevalence was 24% in Madibeng and 22% in Mbekweni. HIV incidence rates based on seroconversions over 12 months were 6.0/100 person-years (PY) (95% CI 3.0, 9.0) in Madibeng and 4.5/100 PY (95% CI 1.8, 7.1) in Mbekweni and those estimated by cross-sectional BED testing were 7.1/100 PY (95% CI 2.8, 11.3) in Madibeng and 5.8/100 PY (95% CI 2.0, 9.6) in Mbekweni. The 12-month pregnancy incidence rates were 4.8/100 PY (95% CI 2.2, 7.5) in Madibeng and 7.0/100 PY (95% CI 3.7, 10.3) in Mbekweni; rates decreased over time in both districts. Genital symptoms were reported very frequently, with an incidence of 46.8/100 PY (95% CI 38.5, 55.2) in Madibeng and 21.5/100 PY (95% CI 15.8, 27.3) in Mbekweni. Almost all (>99%) participants said that they would be willing to participate in a microbicide trial. Conclusion: These populations might be suitable for Phase III microbicide trials provided that HIV incidence rates over time remain sufficiently high to support endpoint-driven trials. © 2011 Nel et al.
Authors & Co-Authors
Nel, Annaléne M.
United States, Silver Spring
International Partnership for Microbicides
Louw, Cheryl Emily
South Africa, Brits
Madibeng Centre for Research
Hellström, Elizabeth
South Africa, Western Cape
Be Part Yoluntu Centre
Braunstein, Sarah L.
United States, New York
New York City Department of Health and Mental Hygiene
Treadwell, Ina
South Africa, Western Cape
Be Part Yoluntu Centre
Marais, Melanie
South Africa, Western Cape
Be Part Yoluntu Centre
de Villiers, Martie
South Africa, Brits
Madibeng Centre for Research
Hugo, Jannie
South Africa, Brits
Madibeng Centre for Research
Paschke, Inge
South Africa, Western Cape
Be Part Yoluntu Centre
Andersen, Chrisna
South Africa, Western Cape
Be Part Yoluntu Centre
van de Wijgert, Janneke H.H.M.
Netherlands, Amsterdam
Amsterdam Umc - University of Amsterdam
Statistics
Citations: 14
Authors: 11
Affiliations: 5
Identifiers
Doi:
10.1371/journal.pone.0021528
e-ISSN:
19326203
Research Areas
Infectious Diseases
Maternal And Child Health
Sexual And Reproductive Health
Study Design
Cross Sectional Study
Cohort Study
Study Approach
Quantitative
Study Locations
South Africa
Participants Gender
Female